Human papillomavirus (HPV) vaccination is safe and efficacious in women without HIV. While good immunogenicity has been observed in women living with HIV (WLWH), efficacy data in this population are needed. We enrolled 420 females aged ≥9 years (range: 9-65) living with HIV. Participants were to receive 3 doses of qHPV vaccine (0/2/6 months). The main endpoint was vaccine failure (i.e., incident persistent qHPV infection, cervical intraepithelial neoplasia of grade 2 or higher (CIN2+), or genital warts). We compared these rates to published rates in vaccinated and unvaccinated women without HIV as well as unvaccinated WLWH.
